%0 Case Reports
%T A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.
%A Lanfranchi C
%A Rizza C
%A Russo MC
%A Borzani I
%A Angileri SA
%A Nazzari E
%A Alicandro G
%A Blasi F
%A Daccò V
%J Int J Infect Dis
%V 147
%N 0
%D 2024 Jul 23
%M 39053617
%F 12.074
%R 10.1016/j.ijid.2024.107190
%X The introduction of CFTR modulator drugs like elexacaftor-tezacaftor-ivacaftor (ETI) has transformed the management of cystic fibrosis (CF), significantly improving symptoms, lung function, and quality of life, while reducing reliance on intravenous antibiotics. However, respiratory exacerbations in the CFTR modulators era remain poorly understood from both pathophysiological and clinical perspectives. We present the case of a 20-year-old Caucasian woman with CF (F508del/L1077P) who, after three years of ETI treatment, experienced a severe episode of hemoptysis, despite being almost asymptomatic in the weeks leading up to admission, requiring bronchial artery embolization. Following ETI treatment, auscultatory findings and FEV1 changes may be less significant, making the detection of respiratory exacerbation more challenging. This highlights the need for heightened vigilance in managing such cases and underscores the challenge of diagnosing and managing exacerbations in the era of modulators. Long term real-world studies are essential to comprehend the evolving course of the disease during ETI treatment.